Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice J M, Boone P, Meyer U A
Laboratoire de Biochimie et Biologie Moléculaire de l'Höpital Calmette, Centre Hospitalier Régional et Universitaire de Lille, France.
Pharmacogenetics. 1995 Dec;5(6):373-84. doi: 10.1097/00008571-199512000-00006.
To detect mutations in the cytochrome P450 CYP2D6 gene (CYP2D6), we developed a strategy based on single-strand conformation polymorphism (SSCP) analysis of the gene amplified by polymerase chain reaction (PCR). The efficiency of the method was evaluated by analysing DNA samples from extensive metabolizers (EM) and poor metabolizers (PM) of debrisoquine. Haplotypes, alleles and mutations of CYP2D6 had previously been characterized in each individual using PCR assays, Xba I restriction fragment length polymorphism (RFLP) and sequencing. PCR-SSCP results were in complete agreement with those obtained using established methods. All previously characterized mutations were associated with particular shifts in the electrophoretic mobility of DNA fragments allowing their identification. We further tested the efficiency of PCR-SSCP for detecting new CYP2D6 mutations. DNA from a PM subject presumed to carry an unknown non-functional mutant allele of CYP2D6 was amplified and bands with aberrant migration patterns were observed on SSCP gels. Sequence analysis of the corresponding DNA fragments revealed the causative mutations. In this way, a novel non-functional allele of the gene, carrying three previously reported mutations and a new mutation in the third exon which results in a premature termination codon, was characterized. Finally, CYP2D6 SSCP analysis was performed on DNA amplified with fluorescent primers and an automated DNA sequencer was used for SSCP analysis of products. We conclude that the PCR-SSCP approach is a powerful method of identifying simultaneously known and new mutations of the CYP2D6 gene.
为了检测细胞色素P450 CYP2D6基因(CYP2D6)中的突变,我们基于聚合酶链反应(PCR)扩增基因的单链构象多态性(SSCP)分析开发了一种策略。通过分析异喹胍的广泛代谢者(EM)和代谢不良者(PM)的DNA样本评估了该方法的效率。先前已使用PCR检测、Xba I限制性片段长度多态性(RFLP)和测序对每个个体的CYP2D6单倍型、等位基因和突变进行了表征。PCR-SSCP结果与使用既定方法获得的结果完全一致。所有先前表征的突变都与DNA片段电泳迁移率的特定变化相关,从而能够对其进行识别。我们进一步测试了PCR-SSCP检测新的CYP2D6突变的效率。扩增了一名推测携带未知的CYP2D6无功能突变等位基因的PM受试者的DNA,并在SSCP凝胶上观察到具有异常迁移模式的条带。对相应DNA片段的序列分析揭示了致病突变。通过这种方式,鉴定了该基因的一个新的无功能等位基因;它携带三个先前报道的突变以及第三个外显子中的一个新突变,该新突变导致提前终止密码子。最后,使用荧光引物扩增的DNA进行CYP2D6 SSCP分析,并使用自动DNA测序仪对产物进行SSCP分析。我们得出结论,PCR-SSCP方法是同时鉴定CYP2D6基因已知和新突变的有力方法。